T. Rowe Price Associates’s Parabilis Medicines PBLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.8M Buy
766,727
+14,780
+2% +$516K ﹤0.01% 1049
2026
Q2
$20.6M Buy
+751,947
New +$20.8M ﹤0.01% 1142

Other funds holding PBLS

T. Rowe Price Associates's PBLS Position: Q3 2026 in Review

T. Rowe Price Associates increased its Parabilis Medicines (PBLS) stake by 2% in Q3 2026, buying an estimated $516K and bringing the position to 766,727 shares worth $24.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

T. Rowe Price Associates first reported a position in PBLS in Q2 2026 and has held it in 2 quarters since. 127 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.

  • T. Rowe Price Associates held 766,727 shares of Parabilis Medicines worth $24.8M as of Q3 2026.
  • T. Rowe Price Associates bought 14,780 Parabilis Medicines shares in Q3 2026, an estimated $516K.
  • Parabilis Medicines made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q3 2026, its #1049 holding.
  • T. Rowe Price Associates first reported a position in Parabilis Medicines in Q2 2026 and has held it in 2 quarters since.
  • 127 funds tracked by Wall St. Rank held Parabilis Medicines as of Q3 2026.

Based on T. Rowe Price Associates's 13F filing for Q3 2026, filed 16 Nov 2026.